Andrew Rundle1, Alfred I Neugut. 1. Department of Epidemiology, Mailman School of Public Health, and Herbert Irving Comprehensive Cancer Center, Columbia University, New York, New York 10032, USA.
Abstract
BACKGROUND: Prior reports suggest that obesity is inversely associated with screening prostate-specific antigen (PSA) levels and may reduce screening sensitivity. METHODS: We evaluated data on 10,623 men screened for prostate cancer during an annual physical examination program administered by EHE International, Inc., between 1/1/2004 and 6/30/2006. Of these, 3,623 men returned for additional physical exams during this period. We used multivariate linear regression analyses to determine whether higher BMI was inversely associated with PSA, and whether BMI, or change in BMI, was associated with change in PSA levels over time. We also developed a theoretical model for the effect of obesity on PSA levels in which increased plasma volume in the obese dilutes PSA levels. RESULTS: After control for age and race/ethnicity, higher BMI was associated with lower PSA levels; men with a BMI > or =40 had a geometric mean PSA level 0.14 ng/ml lower than men with a BMI <25 (P < 0.001). Prospectively, BMI at initial screening and change in BMI over 2 years were not associated with change in PSA or PSA velocity. Our theoretical model accurately predicted observed PSA levels and suggests that a screening PSA of 4.0 ng/ml in normal weight and overweight men corresponds to 3.5 ng/ml in obese men and 3.1 ng/ml in morbidly obese men. CONCLUSION: Across the study population, increased BMI was significantly inversely associated with lower PSA. Based on a theoretical model in which increased plasma volume in the obese dilutes PSA levels we propose new cut-points for a positive screening test. Copyright 2008 Wiley-Liss, Inc.
BACKGROUND: Prior reports suggest that obesity is inversely associated with screening prostate-specific antigen (PSA) levels and may reduce screening sensitivity. METHODS: We evaluated data on 10,623 men screened for prostate cancer during an annual physical examination program administered by EHE International, Inc., between 1/1/2004 and 6/30/2006. Of these, 3,623 men returned for additional physical exams during this period. We used multivariate linear regression analyses to determine whether higher BMI was inversely associated with PSA, and whether BMI, or change in BMI, was associated with change in PSA levels over time. We also developed a theoretical model for the effect of obesity on PSA levels in which increased plasma volume in the obese dilutes PSA levels. RESULTS: After control for age and race/ethnicity, higher BMI was associated with lower PSA levels; men with a BMI > or =40 had a geometric mean PSA level 0.14 ng/ml lower than men with a BMI <25 (P < 0.001). Prospectively, BMI at initial screening and change in BMI over 2 years were not associated with change in PSA or PSA velocity. Our theoretical model accurately predicted observed PSA levels and suggests that a screening PSA of 4.0 ng/ml in normal weight and overweight men corresponds to 3.5 ng/ml in obesemen and 3.1 ng/ml in morbidly obesemen. CONCLUSION: Across the study population, increased BMI was significantly inversely associated with lower PSA. Based on a theoretical model in which increased plasma volume in the obese dilutes PSA levels we propose new cut-points for a positive screening test. Copyright 2008 Wiley-Liss, Inc.
Authors: Andrew Rundle; Yun Wang; Sudha Sadasivan; Dhananjay A Chitale; Nilesh S Gupta; Deliang Tang; Benjamin A Rybicki Journal: Prostate Date: 2017-03-27 Impact factor: 4.104
Authors: Donna P Ankerst; Brad H Pollock; Yuanyuan Liang; Nidzara Dizdarevic; Sergiy Kyrylenko; Andreas Boeck; Ian M Thompson; Robin Leach Journal: Urology Date: 2011-05-07 Impact factor: 2.649
Authors: Lionel L Bañez; Simone Albisinni; Stephen J Freedland; Andrea Tubaro; Cosimo De Nunzio Journal: World J Urol Date: 2012-07-31 Impact factor: 4.226
Authors: Andrew Rundle; Michelle Jankowski; Oleksandr N Kryvenko; Deliang Tang; Benjamin A Rybicki Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-04-23 Impact factor: 4.254
Authors: Aruna V Sarma; James Hotaling; Rodney L Dunn; Patricia A Cleary; Barbara H Braffett; Catherine Kim; Catherine Martin; William Herman; Patricia Gatcomb; Alan M Jacobson; Sarah K Holt; Hunter Wessells Journal: J Urol Date: 2014-09-11 Impact factor: 7.450